Biological Dynamics Selected As Finalist for the 2022 AACC Disruptive Technology Award; Award Recognizes the Company’s Verita™ Isolation Platform, Which Seeks to Enable Early-Stage Cancer Detection

On June 14, 2022, Biological Dynamics, Inc., a biotechnology company focused on detecting diseases at their earliest stages, today announced that the company and its platform technology, Verita™, have been selected as a 2022 finalist by the American Association for Clinical Chemistry (AACC) for their Disruptive Technology Award competition. “We’re honored to be selected as a finalist by the AACC’s panel for this award, which recognizes the power of our differentiated multiomics platform technology,” said Dr. Paul Billings, CEO and Director of Biological Dynamics. “We are excited to continue building evidence for our first clinical application by enabling the isolation and characterization of exosomes into a unique early-stage cancer detection algorithm and assay.” The Verita™ Isolation Platform is Biological Dynamics’ proprietary platform, which uses AC Electrokinetics (ACE) technology for isolation of nanoparticles and macromolecules from biofluids, such as whole blood, plasma, serum, urine, and saliva. Using the Verita™ platform, the company recently received an FDA Breakthrough Device Designation for its first liquid biopsy assay for the early detection of pancreatic ductal adenocarcinoma using exosomal proteins.

Login Or Register To Read Full Story